Viral Hepatitler
Özet
Viral hepatitler, hepatovirus ailesine ait beş virüsün neden olduğu, akut veya kronik enfeksiyonlara yol açabilen ve küresel bir sağlık sorunu teşkil eden hastalıklardır. Kronik enfeksiyonlar uzun vadede karaciğer sirozu ve hepatoselüler kanser gibi ölümcül komplikasyonlara yol açabilirken, bazı türleri aşıyla önlenebilmektedir. Hepatit A, fekal-oral yolla bulaşan, kendini sınırlayan ve kronikleşmeyen bir türdür; tanısı anti-HAV IgM ile konur. Hepatit B (HBV) enfeksiyonu, dünya genelinde milyonlarca insanı etkileyen ve yenidoğan döneminde bulaştığında %90 oranında kronikleşen küresel bir sorundur. HBV replikasyonu ve konak immün yanıtı arasındaki ilişki, hastalığın klinik seyrini ve immün toleranstan klerense kadar olan evrelerini belirler; tedavisinde nükleot(z)id analogları tercih edilir. Defektif bir virüs olan Hepatit D, enfeksiyon geliştirmek için HBV'nin varlığına ihtiyaç duyar ve tedavisinde pegile interferon alfa kullanılır. Moleküler yapısı varyasyonlara oldukça açık bir RNA virüsü olan Hepatit C (HCV) ise perkütan yolla, özellikle intravenöz ilaç kullanımıyla bulaşır. Genellikle asemptomatik seyreden akut HCV, yüksek oranda kronikleşme eğilimindedir. Günümüzde HCV tedavisinde, virüsün genotipine göre belirlenen direkt etkili antiviral ilaç kombinasyonları başarıyla uygulanmakta ve siroz ile kanser riski azaltılmaktadır.
Viral hepatitis represents a major global health challenge caused by five distinct viruses of the hepatovirus family, which can lead to both acute and chronic infections. In the long term, chronic presentations may progress to severe complications such as liver cirrhosis and hepatocellular carcinoma, though certain types are completely preventable through vaccination. Hepatitis A is a self-limiting, non-chronic infection primarily transmitted via the fecal-oral route and diagnosed by anti-HAV IgM antibodies. Hepatitis B virus (HBV) affects millions worldwide and carries a 90% risk of chronicity when acquired perinatally. The clinical course of HBV is defined by the interaction between viral replication and host immune response, moving through distinct phases where nucleot(z)ide analogs serve as the primary treatment strategy. Hepatitis D is a defective virus that strictly requires the presence of HBV to replicate, routinely managed with pegylated interferon alpha. Hepatitis C virus (HCV) is a highly variable RNA virus predominantly transmitted through percutaneous routes, especially intravenous drug use. Acute HCV is characteristically asymptomatic but shows a strong propensity to become chronic. Modern management of HCV relies on genotype-specific, direct-acting antiviral combinations to effectively achieve virological cure and minimize liver disease progression.
Referanslar
MacCallum FO. Homologous serum jaundice. Lancet 1947; 2:691.
Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 1973; 182:1026.
Klevens RM, Miller JT, Iqbal K, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005-2007. Arch Intern Med 2010; 170:1811.
Centers for Disease Control and Prevention. Viral Hepatitis Surveillance:United States, 2013 US Department of Health and Human Services, Atlanta, GA 2016. (30.10.2021 tarihinde https://www.cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014HepSurveillanceRpt_Rev2016-09-26.pdf adresinden ulaşılmıştır).
World Health Organization. Global Alert and Response (GAR): Hepatitis A. (30.10.2021 tarihinde http://www.who.int/csr/disease/hepatitis/whocdscsredc2007/en/index4.html#estimated adresinden ulaşılmıştır).
Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. (30.10.2021 tarihinde http://www.cdc.gov/hepatitis/hav/havfaq.htm#general adresinden ulaşılmıştır).
Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194.
Vallbracht A, Fleischer B, Busch FW. Hepatitis A: hepatotropism and influence on myelopoiesis. Intervirology 1993; 35:133.
Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985; 313:1059.
Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226.
Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171 Suppl 1:S15.
Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10 Suppl 1:S15.
Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.
Kemmer NM, Miskovsky EP. Hepatitis A. Infect Dis Clin North Am 2000; 14:605.
Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101:635.
Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992; 71:14.
Centers for Disease Control and Prevention (CDC). Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis--United States, 2002-2004. MMWR Morb Mortal Wkly Rep 2005; 54:453.
The World Health Organization. Global Hepatitis Report, 2017. (30.10.2021 tarihinde https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=DC3616B5BDF94F A8B6AC2FDBC71E5B51?sequence=1 adresinden ulaşılmıştır).
Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92:1844.
Centers for Disease Control. Surveillance for viral hepatitis – United States, 2013 (30.10.2021 tarihinde http:// www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm#hepatitisB adresinden ulaşılmıştır).
World Health Organization. Guidelines on assessing donor suitability for blood donation. (30.10.2021 tarihinde http://iacld.ir/DL/elm/whoblooddonorselectionguidelinesonassessingdonorsuitability forblooddonation.pdf adresinden ulaşılmıştır).
Liaw YF, Tsai SL, Sheen IS, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93:354.
Garfein RS, Bower WA, Loney CM, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40:865.
Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104.
Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol 2010; 8:541.
Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110.
Yan LB, Liao J, Han N, et al. Association between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study. Sci Rep 2020; 10:6738.
Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007; 5:636
McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759.
Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 2010; 8:535.
Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV DNA and anti-HBe. Gastroenterology 1986; 90:1268.
Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139:474.
Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123:1084.
Lin CL, Tseng TC, Kao JH. What can we learn from hepatitis B virus clinical cohorts? Liver Int 2015; 35 Suppl 1:91.
The World Health Organziaiton. Guidelines for the prevention, care, and treatment of persons with chronic hepaititis B infection. (30.10.2021 tarihinde http://apps.who.int/iris/bitstream/10665/15459 0/1/9789241549059_eng.pdf?ua=1 adresinden ulaşılmıştır).
Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8:766
Kleinman SH, Kuhns MC, Todd DS, et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43:696.
Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588.
Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36:543.
Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45:97.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370
Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol 2016; 2016:5234969.
Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987; 1:478.
Negro F, Bergmann KF, Baroudy BM, et al. Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. J Infect Dis 1988; 158:151.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
Negro F, Shapiro M, Satterfield WC, et al. Reappearance of hepatitis D virus (HDV) replication in chronic hepatitis B virus carrier chimpanzees rechallenged with HDV. J Infect Dis 1989; 160:567.
Longo DL, Fauci AS. (2013). Harrison’s Gastroenterology and Hepatology (2nd Edition;357-385). USA, Mc Graw-Hill Education.
World Health Organization. Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015. In: Global hepatitis report 2017. (30.10.2021 tarihinde https://apps.who.int/iris/bitstream/handle/10665/277005/WHO-CDS-HIV-18.46-eng.pdf adresinden ulaşılmıştır).
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011 Aug 13;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0. Epub 2011 Jul 27. PMID: 21802134; PMCID: PMC3285467.
Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991 Aug 15;325(7):454-60. doi: 10.1056/NEJM199108153250702. PMID: 1649402.
Roth D, Zucker K, Cirocco R, DeMattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int. 1994 Jan;45(1):238-44. doi: 10.1038/ki.1994.29. PMID: 7510350.
Koike K, Tsutsumi T. The Oncogenic Role of Hepatitis C Virus. Recent Results Cancer Res. 2021;217:91-105. doi: 10.1007/978-3-030-57362-1_5. PMID: 33200363.
Hepatit C Tedavi Kılavuzu Güncellemesi (2019). (30.10.2021 tarihinde https://www.vhsd.org/tr/hepatit-c-tedavi-kilavuzu-guncellemesi-a adresinden ulaşılmıştır).
Idilman R, Razavi H, Robbins-Scott S et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res. 2020 Mar 24;20(1):249. doi: 10.1186/s12913-020-5019-8. PMID: 32209103; PMCID: PMC7093960.
